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Background: One of the main glycoproteins responsible for angiogenesis is the vascular endothelial growth factor.
It is believed that C936T polymorphism, located in the VEGF gene, is correlated with susceptibility towards development
of sporadic colorectal adenocarcinoma. The aim of this study was to identify the frequencies of the genotypes of C936T
polymorphism of the VEGF gene in patients with sporadic colorectal adenocarcinoma, in comparison with controls, and
whether this correlates with the degree of tumor invasion, lymph node involvement and occurrence of metastases at the
time of the diagnosis. The analysis was done on 261 patients with sporadic colorectal adenocarcinoma and 261 controls.
The genotypes of C936T polymorphism were evaluated by means of the polymerase chain reaction and enzyme digestion,
using peripheral blood samples.
Results: The occurrences of genotype 936CC were similar in the two groups (80.5% versus 78.5%, p = 0.2288). In relation to
tumor location, lymph node involvement, infiltration and tumor metastasis, no statistically significant results were obtained
(p = 0.3116, p = 0.8485, p = 0.9408 and p = 0.2861, respectively).
Conclusion: C936T polymorphism of the VEGF gene did not influence the occurrence of sporadic colorectal
adenocarcinoma development and did not correlated with the degree of tumor invasion, lymph node
involvement and occurrence of metastases.
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Sporadic colorectal adenocarcinoma (SCA) is the third
most frequent type of cancer among men and the second
among women in the southern and southeastern regions
of Brazil [1]. According to the Heath Department of
Campinas, this type of cancer is the second biggest cause
of death among women [2]. One of the main glycoproteins
responsible for angiogenesis, with important action relat-
ing to cell proliferation survival and migration, along with
mediation of vascular permeability, is the vascular endo-
thelial growth factor (VEGF) and its receptors [3-5].* Correspondence: laurabio@gmail.com
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unless otherwise stated.Increased expression of VEGF has been correlated with
worse prognosis in colorectal cancer cases [6-8].
C936T polymorphism (rs3025039) is located in the
VEGF-A gene, and consists of replacement of a single
nucleotide (SNP) in exon 8 in the non-translated 3’ region
(3’UTR) [9], with replacement of the cytosine base (C) by
thymine (T) [10-13], thus resulting in loss of the region
that transcribes the factor AP-4 (activated protein 4). Ana-
lyses on the complementary DNA product (cDNA) have
suggested that AP-4 codes for the protein HLH, and that
this protein recognizes specific sites in the CAGCTG
DNA sequence [14].
In the presence of the wild genotype, the glycoprotein
level in plasma increases, thus stimulating formation of
new vessels [15-19]. According to RENNER et al. [20],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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low serum levels of VEGF, thus diminishing angiogenesis
and the risk of acquiring cancer. This hypothesis has been
corroborated by other authors, who found that the T allele
had a protective effect regarding the risk of developing
malignant neoplasm or even a less aggressive tumor
[12,15,21,22]. On the other hand, Hofmann et al. [21] and
Dassaoulas et al. [22] did not identify any association be-
tween SCA and C936T polymorphism of the VEGF gene.
A meta-analysis conducted by Xu et al. [23] containing
13,293 cancer cases and 12,308 controls did not show any
association between SCA and C936T polymorphism of the
VEGF gene. However, other authors have shown that the T
allele was associated with higher risk of SCA and other
type of malignant neoplasm [18], colorectal adenoma [24],
gastric cancer [19] and oral cancer [25]. These authors
believed that the heterozygote variant genotype CT was
responsible for the increased occurrence of neoplasm,
but also stated that the results could vary between differ-
ent ethnic groups, with different expressions in different
populations.
Some authors have compared the histopathological char-
acteristics of SCA with this polymorphism, but the results
have been divergent. Neither Hofmann nor Dassoulas found
that VEGF C936T polymorphism had association with
size, tumor differentiation, tumor stage and presence of
lymph node metastasis or age group. Chae et al. [26] ob-
tained similar results, but Lurje et al. [27] demonstrated
that the wild genotype CC was related to recurrence in
stage III of SCA.
The aim of this study was to investigate whether VEGF
C936T polymorphism influenced the risk of development
of SCA, and whether, in individuals with this neoplasm, it
might correlate with the degree of tumor invasion, lymph
node involvement and occurrence of metastases at the time
of the diagnosis. The Ethics Committee of the School of
Medical Sciences, UNICAMP, approved this study under
opinion report no. 759/2007.
Methods
Assessments were made on 261 patients with SCA, both
genders, of mean age 65.2 years (range: 32–97), and 261
controls comprising blood donors of both genders and
mean age 52.9 years (range: 25–60). The groups were
matched according to sex and racial group. Consent for
participation in the study was obtained from all partici-
pants. The characteristics analyzed were tumor location,
lymph node involvement, occurrence of metastases and
tumor stage. The tumor was established in accordance
with the criteria of the AJCC Cancer Staging Manual [28].
With regard to tumor location, tumors were described as
right-colon tumors if they were in the cecum, ascending
colon or transverse colon; left-colon tumors if they were
in the descending colon or sigmoid; or rectal tumors ifthey were located up to 18 cm from the anal margin. In re-
lation to tumor infiltration, the patients were divided into
two groups: Tis, T1 and T2 lesions; or T3 and T4 lesions.
With regard to lymph node involvement, occurrence or
non-occurrence of metastasis was taken into account,
independent of the number of lymph nodes involved. In
terms of the TNM classification, the patients were grouped
into states I and II versus III and IV.
C936T polymorphism was evaluated in peripheral blood
samples. The polymorphism analysis was done in accord-
ance with the methods described by Renner et al. [21],
using the polymerase chain reaction, followed by enzyme
digestion using the endonuclease restriction enzyme NlaIII.
The forward primers used was 5’- AAG GAA GAG ACT
CTG CGC AGA GC - 3’ and the reverse primer was 5’ -
TAA ATG TAT GTA TGT GGG TGG GTG TGT CTA
CAG G - 3’.
A test to verify Hardy-Weinberg equilibrium was per-
formed with the aim of finding out whether there was any
preferential distribution of any of the genotypes evaluated
in the patient and control groups of this study. The statis-
tical significance of the differences between the groups was
calculated by means of the Fisher exact test and chi-square
test, using the “diagnose parameters α” software (developed
by one of the collaborators), Epi Info version 6.04d (CDC,
Atlanta, Georgia, USA) and Excel 2010 (Microsoft). The
statistical significance level was set at p < 0.05.
Results
The sample size calculation, according to the frequencies
of polymorphisms was 237.72. The Hardy-Weinberg test
was applied to both controls and patients. Both were in
equilibrium (X2 = 0.019, p = 0.89; and X2 = 0.587, p = 0.4436,
respectively), for the locus of VEGF C936T polymorphism.
Similar frequencies were seen between patients and controls,
with a relative risk (OR) of 1.47 (95% CI: 0.80-2.70), ad-
justed according to age and frequency between the geno-
types, without any statistically significant result (p = 0.737)
(Table 1).
To analyze the polymorphism, 261 patients with sporadic
colorectal adenocarcinoma and 261 controls were evalu-
ated. With regard to tumor infiltration and lymph node
involvement, 93 patients with rectal neoplasm and neo-
adjuvant therapy were excluded. One case was not classi-
fied in relation to tumor location because of lack of data
in the medical records, and 19 did not undergo surgical
treatment and did not present a TNM classification.
Table 2 shows the number of patients analyzed in relation
to the characteristics analyzed.
No significant differences were identified in relation to
tumor invasion (p = 0.9408; OR = 1.0968, 95% CI: 0.4479-
2.6854), lymph node involvement (p = 0.8485; OR = 0.9275,
95% CI: 0.4286-2.0072), occurrence of metastases (p =
0.2861; OR = 1.0361, 95% CI: 0.5010-30.9979), tumor







CC 210 (50.6) 205 (49.4) 1.00 (reference)
0.7370CT 48 (47.1) 54 (52.9) 1.14 (0.75 to 1.72)
TT 3 (60) 2 (40) 0.68 (0.11 to 4.10)
Table 3 VEGF genotype in sporadic colorectal cancer











Caucasian 219 (84,9) 173 (66,3) 46 (17,6)
0.4693
African-American 42 (16,1) 33 (12,6) 9 (3,4)
Metastasis 261
0.7843No 211 (80,8) 166 (63,6) 45 (17,2)
Yes 50 (19,2) 40 (15,3) 10 (3,8)
Survival
0.2619




N+ 80 (48,5) 64 (38,8) 16 (9,7)
0.8485
N0 85 (51,5) 69 (41,8) 16 (9,7)
Infiltration 165
Tis-T2 39 (23,6) 31 (18,8) 8 (4,8)
0.9408
T3-T4 126 (76,4) 102 (61,8) 24 (14,5)
Tumor location 260
Rectum 137 (52,7) 106 (41,1) 29 (11,2)
0.3116Left Colon 79 (30,4) 60 (23,3) 19 (7,4)
Right Colon 44 (16,9) 39 (15,1) 5 (1,9)
TNM 226
0.6045I + II 139 (61,5) 109 (48,2) 30 (13,3)
III + IV 87 (38,5) 69 (30,5) 18 (8)
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or TNM (p = 0.6045; OR = 1.0550, 95% CI: 0.5466-2.0363)
(Table 3).
Discussion
Angiogenesis performs an essential role in tumor growth
and invasion, and in occurrence of metastases, and it may
be stimulated through production of factors generated by
neoplastic cells [29,30]. Among the factors that regulate
angiogenesis, VEGF is the best known and, given its cap-
acity to stimulate vascular proliferation, its expression is
thought to have the capacity to modify the biological
behavior of solid tumors, including SCA. However, the
human VEGF gene is highly polymorphic, thus enabling
wide variation in its expression between individuals.
It is now known that VEGF is not limited to angiogen-
esis and vascular permeability, it can also be an autocrine
and damage the functions of immune cells found in the
tumor microenvironment and therefore affecting the mass
response to tumors. The increase in the synthesis of VEGF
can be detected plasma in advanced tumors. The VEGF
receptor (VEGFR1) promotes the migration and invasion
of colorectal tumor cells besides maintaining their survival
[31]. In the presence of wild genotype (CC), glycoprotein
level in plasma increases, stimulating the development of
new vessels [15,16,18,19,32].
It is believed that VEGF C936T polymorphism interferes
with production of the protein VEGF [20]. The homozygote
variant genotype TT has been associated with lower plasma
levels of this protein [27]. Thus, the TT genotype would
diminish angiogenesis and, in theory, would give rise to
less tumor development. It is known that higher preopera-
tive serum levels of VEGF in individuals with SCA has







VEGF polymorphism 261 261 -
Metastasis 261 - -
Tumor location 260 - 1
Survival 258 - 3
Infiltration (T) 165 - 96
Lymph node (N) 165 - 96However, studies on this polymorphism in different solid
tumors have presented different results in relation to the
risk of cancer or prognostic factors [9,13,34]. Oliveira
et al. [34] demonstrated that the wild genotype (CC) is
a determinant for greater aggressiveness of sporadic breast
tumors.
In gastric cancer cases, Tzanakis et al. [19] found that
a strong association between the C936T gene and the TT
genotype was related to greater tumor size. However, the
results from the present study, along with the results from
Hofmann and Dassoulas, do not support the existence
of associations with tumor size, histological grade, tumor
stage, lymph node metastases or age at the time of diagno-
sis, in SCA cases. On the other hand, Chae [26] showed
that the T allele was related to the advanced stage of SCA
(metastasis).
These data suggest that the contribution of each geno-
type to the tumor characteristics may be closely related to
the type of organ that is bearing the malignant growth.
The present study suggests that the genotypes studied
did not increase the risk of SCA (CT vs. CC =OR 1.47, 95%
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3.63). These findings were corroborated by Hofmann [22],
Dassaoulas [23], Xu [24] and coworkers, obtaining the same
results in relation to C936T polymorphism. Divergent
findings were obtained by Eroglu and Wu [18,35], in a
study that showed that this polymorphism increased the
patient’s predisposition towards developing a malignant
tumor, even though the frequencies of the variants in their
study were similar to those in other studies [12,36].
These data can be explained by the action of a variety
of factors, such as the variation in the locus, action by
several other genes, environmental characteristics and eth-
nicity, which therefore provides justification for studying
this in different populations. Hefler et al. [37] reported that
simultaneous presence of three homozygote genotypes
(2578/CC, 1154/GG and 634/CC) increased the serum
levels of VEGF and was correlated with shorter survival,
among 563 patients with ovarian cancer. Thus, in addition
to the sequential variation in the VEGF gene that may
alter its production or activity, other angiogenic factors
present in the circulation could, through interacting with
VEGF, influence its role in the pathogenesis of cancers.
The analysis on polymorphism in relation to location,
tumor infiltration, lymph node involvement, occurrence of
metastases and staging did not show any significant differ-
ences. These findings differed from those of Bae et al. [36],
who observed that occurrences of the T allele increased the
risk in men under the age of 55 years and in all women,
and that this was associated with greater occurrence of
adenocarcinoma in the right colon. These results can be
explained in terms of ethnic differences.
In the present study, C936T polymorphism did not
change the risk of developing SCA. Our results are con-
cordant with those of Hofmann et al. [21], Dassoulas et al.
[22] and Wu et al. [35], who suggested that the C2578A,
G634C and C936T polymorphisms were not general risk
factors for SCA. Analysis on C936T polymorphism of the
VEGF gene, as done in the present study, has also been
conducted on cases of breast, lung and stomach cancer and
on melanoma [9,19,38]. C936T polymorphism of the VEGF
gene was found not to significantly influence the suscepti-
bility to breast cancer in the study by Jin et al. [39]. On the
other hand, individuals with the T allele in cases of VEGF
936 presented diminished risk of breast and lung cancer,
according to other researchers [12,13]. These results are
not unexpected, since VEGF functions as a fundamental
mediator of angiogenesis, thereby influencing biological
and phenotypic characteristics (tumor size, histological
grade, disease stage and metastatic potential), rather
than defining the susceptibility to cancer development.
Conclusion
Polymorphism of the VEGF C936T gene did not influence
the occurrence of SCA development and was not correlatedwith the degree of tumor invasion, lymph node involve-
ment or occurrence of metastases.
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